RxDoctor Payments Data

Stephanie McLain

Family · Queensbury, NYNPI 1548954878

Payments from drug & device makers

$880in general payments, 2019–2025

Across 41 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$207
  • E.r. Squibb & Sons, L.L.C.$148
  • Pfizer$76
  • Merck$69
  • Actelion Pharmaceuticals US, Inc.$59
  • Kiniksa Pharmaceuticals International, PLC$49
  • plus $270 from 12 others

What the payments were for

  • Food & beverage$880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$880 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$24,912
Medicare patients
302
Services billed
377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$33,585
EntrestoSacubitril/Valsartan24$32,011
BrilintaTicagrelor34$15,271
MultaqDronedarone Hcl14$11,021
Metoprolol Succinate102$1,224
Nifedipine ErNifedipine14$799
Bumetanide20$508
Atorvastatin Calcium42$500
Isosorbide Mononitrate ErIsosorbide Mononitrate22$316
Rosuvastatin Calcium22$308
Losartan Potassium13$283
Amiodarone Hcl19$242
Ezetimibe13$212
Metoprolol Tartrate25$122
Torsemide13$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$33,58527 claims
NovartisEntresto$14$32,01124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,883 family providers in New York.

Other family in Queensbury

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →